KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Xenon Pharmaceuticals (XENE) Return on Capital Employed (2016 - 2025)

Historic Return on Capital Employed for Xenon Pharmaceuticals (XENE) over the last 12 years, with Q3 2025 value amounting to 0.57%.

  • Xenon Pharmaceuticals' Return on Capital Employed fell 2600.0% to 0.57% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.57%, marking a year-over-year decrease of 2600.0%. This contributed to the annual value of 0.33% for FY2024, which is 700.0% down from last year.
  • As of Q3 2025, Xenon Pharmaceuticals' Return on Capital Employed stood at 0.57%, which was down 2600.0% from 0.47% recorded in Q2 2025.
  • Xenon Pharmaceuticals' Return on Capital Employed's 5-year high stood at 0.13% during Q2 2022, with a 5-year trough of 0.57% in Q3 2025.
  • For the 5-year period, Xenon Pharmaceuticals' Return on Capital Employed averaged around 0.27%, with its median value being 0.26% (2021).
  • As far as peak fluctuations go, Xenon Pharmaceuticals' Return on Capital Employed soared by 1200bps in 2022, and later plummeted by -2600bps in 2025.
  • Over the past 5 years, Xenon Pharmaceuticals' Return on Capital Employed (Quarter) stood at 0.2% in 2021, then rose by 11bps to 0.17% in 2022, then plummeted by -56bps to 0.27% in 2023, then crashed by -32bps to 0.36% in 2024, then crashed by -58bps to 0.57% in 2025.
  • Its Return on Capital Employed stands at 0.57% for Q3 2025, versus 0.47% for Q2 2025 and 0.4% for Q1 2025.